Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin
Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apol...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2003-03, Vol.91 (5), p.20-23 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 5 |
| container_start_page | 20 |
| container_title | The American journal of cardiology |
| container_volume | 91 |
| creator | Rader, Daniel J Davidson, Michael H Caplan, Richard J Pears, John S |
| description | Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apolipoprotein [apo] B/apo A-I ratio) have been found to be strong predictors of coronary artery disease (CAD) risk. Three trials that compared the effects of rosuvastatin 10 mg versus atorvastatin 10 mg and 2 trials that compared the effects of rosuvastatin 10 mg versus simvastatin 20 mg and pravastatin 20 mg on lipid ratios in patients with hypercholesterolemia were prospectively designed for pooled analysis. At 12 weeks, in the 3-trial pooled analysis, rosuvastatin 10 mg (n = 389) showed significantly greater reductions in all 4 lipid ratios compared with atorvastatin 10 mg (n = 393) (p |
| doi_str_mv | 10.1016/S0002-9149(03)00005-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73117882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914903000055</els_id><sourcerecordid>73117882</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-a71985ed74e39ad395aa11adfb49bee024b199cb51c11b277a251c9c34e91ec03</originalsourceid><addsrcrecordid>eNqFUU1v1DAQtVARXQo_gcqnCiRSPHGyWXNBqIKCtFIPwNma2BNhtIlTj7cVf4bfivej9MjBGj_7vTeaeUK8AnUJCpbvviml6spAY14r_aYA1VbtE7GAVWcqMKBPxOIf5VQ8Z_5VIEC7fCZOoV42S92ohfizDnPwEqdy5rgJc5xTzBQmmTCHyO8lMkcXdmCS9yH_lC6mOGH6LTFlKsUHJmTae9AwkMss4yBT5O0dci7KqWjGGRP5gwPmmB6-3so54SPYmXAYHx5eiKcDbpheHuuZ-PH50_erL9X65vrr1cd15RrQucIOzKol3zWkDXptWkQA9EPfmJ5I1U0Pxri-BQfQ112HdbkapxsyQE7pM3Fx8C3T326Jsx0DO9pscKK4ZdtpgG61qguxPRBdmY8TDXZOYSzbsKDsLhi7D8butm6VtvtgbFt058cG234k_6g6JlEIHw4EKmPeBUqWXaDJkQ-prNT6GP7T4i9XLqJC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73117882</pqid></control><display><type>article</type><title>Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rader, Daniel J ; Davidson, Michael H ; Caplan, Richard J ; Pears, John S</creator><creatorcontrib>Rader, Daniel J ; Davidson, Michael H ; Caplan, Richard J ; Pears, John S</creatorcontrib><description>Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apolipoprotein [apo] B/apo A-I ratio) have been found to be strong predictors of coronary artery disease (CAD) risk. Three trials that compared the effects of rosuvastatin 10 mg versus atorvastatin 10 mg and 2 trials that compared the effects of rosuvastatin 10 mg versus simvastatin 20 mg and pravastatin 20 mg on lipid ratios in patients with hypercholesterolemia were prospectively designed for pooled analysis. At 12 weeks, in the 3-trial pooled analysis, rosuvastatin 10 mg (n = 389) showed significantly greater reductions in all 4 lipid ratios compared with atorvastatin 10 mg (n = 393) (p <0.001). The mean percent reduction from baseline in the LDL cholesterol/HDL cholesterol ratio was 51% in patients treated with rosuvastatin 10 mg versus 39% in patients treated with atorvastatin 10 mg. In the 2-trial pooled analysis, treatment with rosuvastatin 10 mg (n = 226) also resulted in significantly greater reductions in all 4 lipid ratios compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (p <0.001). Mean percent reductions from baseline in the LDL cholesterol/HDL cholesterol ratio were 52%, 39%, and 30% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in these 2 trials.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/S0002-9149(03)00005-5</identifier><identifier>PMID: 12646340</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Anticholesteremic Agents - therapeutic use ; Apolipoproteins - blood ; Atorvastatin ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Coronary Disease - blood ; Coronary Disease - etiology ; Coronary Disease - prevention & control ; Double-Blind Method ; Europe ; Female ; Fluorobenzenes - therapeutic use ; Heptanoic Acids - therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypercholesterolemia - blood ; Hypercholesterolemia - complications ; Hypercholesterolemia - drug therapy ; Least-Squares Analysis ; Lipids - blood ; Male ; Middle Aged ; Pravastatin - therapeutic use ; Prospective Studies ; Pyrimidines ; Pyrroles - therapeutic use ; Randomized Controlled Trials as Topic ; Rosuvastatin Calcium ; Simvastatin - therapeutic use ; Sulfonamides ; Treatment Outcome</subject><ispartof>The American journal of cardiology, 2003-03, Vol.91 (5), p.20-23</ispartof><rights>2003 Excerpta Medica Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-a71985ed74e39ad395aa11adfb49bee024b199cb51c11b277a251c9c34e91ec03</citedby><cites>FETCH-LOGICAL-c413t-a71985ed74e39ad395aa11adfb49bee024b199cb51c11b277a251c9c34e91ec03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002914903000055$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12646340$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rader, Daniel J</creatorcontrib><creatorcontrib>Davidson, Michael H</creatorcontrib><creatorcontrib>Caplan, Richard J</creatorcontrib><creatorcontrib>Pears, John S</creatorcontrib><title>Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apolipoprotein [apo] B/apo A-I ratio) have been found to be strong predictors of coronary artery disease (CAD) risk. Three trials that compared the effects of rosuvastatin 10 mg versus atorvastatin 10 mg and 2 trials that compared the effects of rosuvastatin 10 mg versus simvastatin 20 mg and pravastatin 20 mg on lipid ratios in patients with hypercholesterolemia were prospectively designed for pooled analysis. At 12 weeks, in the 3-trial pooled analysis, rosuvastatin 10 mg (n = 389) showed significantly greater reductions in all 4 lipid ratios compared with atorvastatin 10 mg (n = 393) (p <0.001). The mean percent reduction from baseline in the LDL cholesterol/HDL cholesterol ratio was 51% in patients treated with rosuvastatin 10 mg versus 39% in patients treated with atorvastatin 10 mg. In the 2-trial pooled analysis, treatment with rosuvastatin 10 mg (n = 226) also resulted in significantly greater reductions in all 4 lipid ratios compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (p <0.001). Mean percent reductions from baseline in the LDL cholesterol/HDL cholesterol ratio were 52%, 39%, and 30% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in these 2 trials.</description><subject>Adult</subject><subject>Aged</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Apolipoproteins - blood</subject><subject>Atorvastatin</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Coronary Disease - blood</subject><subject>Coronary Disease - etiology</subject><subject>Coronary Disease - prevention & control</subject><subject>Double-Blind Method</subject><subject>Europe</subject><subject>Female</subject><subject>Fluorobenzenes - therapeutic use</subject><subject>Heptanoic Acids - therapeutic use</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypercholesterolemia - blood</subject><subject>Hypercholesterolemia - complications</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Least-Squares Analysis</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pravastatin - therapeutic use</subject><subject>Prospective Studies</subject><subject>Pyrimidines</subject><subject>Pyrroles - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Rosuvastatin Calcium</subject><subject>Simvastatin - therapeutic use</subject><subject>Sulfonamides</subject><subject>Treatment Outcome</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUU1v1DAQtVARXQo_gcqnCiRSPHGyWXNBqIKCtFIPwNma2BNhtIlTj7cVf4bfivej9MjBGj_7vTeaeUK8AnUJCpbvviml6spAY14r_aYA1VbtE7GAVWcqMKBPxOIf5VQ8Z_5VIEC7fCZOoV42S92ohfizDnPwEqdy5rgJc5xTzBQmmTCHyO8lMkcXdmCS9yH_lC6mOGH6LTFlKsUHJmTae9AwkMss4yBT5O0dci7KqWjGGRP5gwPmmB6-3so54SPYmXAYHx5eiKcDbpheHuuZ-PH50_erL9X65vrr1cd15RrQucIOzKol3zWkDXptWkQA9EPfmJ5I1U0Pxri-BQfQ112HdbkapxsyQE7pM3Fx8C3T326Jsx0DO9pscKK4ZdtpgG61qguxPRBdmY8TDXZOYSzbsKDsLhi7D8butm6VtvtgbFt058cG234k_6g6JlEIHw4EKmPeBUqWXaDJkQ-prNT6GP7T4i9XLqJC</recordid><startdate>20030306</startdate><enddate>20030306</enddate><creator>Rader, Daniel J</creator><creator>Davidson, Michael H</creator><creator>Caplan, Richard J</creator><creator>Pears, John S</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030306</creationdate><title>Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin</title><author>Rader, Daniel J ; Davidson, Michael H ; Caplan, Richard J ; Pears, John S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-a71985ed74e39ad395aa11adfb49bee024b199cb51c11b277a251c9c34e91ec03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Apolipoproteins - blood</topic><topic>Atorvastatin</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Coronary Disease - blood</topic><topic>Coronary Disease - etiology</topic><topic>Coronary Disease - prevention & control</topic><topic>Double-Blind Method</topic><topic>Europe</topic><topic>Female</topic><topic>Fluorobenzenes - therapeutic use</topic><topic>Heptanoic Acids - therapeutic use</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypercholesterolemia - blood</topic><topic>Hypercholesterolemia - complications</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Least-Squares Analysis</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pravastatin - therapeutic use</topic><topic>Prospective Studies</topic><topic>Pyrimidines</topic><topic>Pyrroles - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Rosuvastatin Calcium</topic><topic>Simvastatin - therapeutic use</topic><topic>Sulfonamides</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rader, Daniel J</creatorcontrib><creatorcontrib>Davidson, Michael H</creatorcontrib><creatorcontrib>Caplan, Richard J</creatorcontrib><creatorcontrib>Pears, John S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rader, Daniel J</au><au>Davidson, Michael H</au><au>Caplan, Richard J</au><au>Pears, John S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2003-03-06</date><risdate>2003</risdate><volume>91</volume><issue>5</issue><spage>20</spage><epage>23</epage><pages>20-23</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><abstract>Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apolipoprotein [apo] B/apo A-I ratio) have been found to be strong predictors of coronary artery disease (CAD) risk. Three trials that compared the effects of rosuvastatin 10 mg versus atorvastatin 10 mg and 2 trials that compared the effects of rosuvastatin 10 mg versus simvastatin 20 mg and pravastatin 20 mg on lipid ratios in patients with hypercholesterolemia were prospectively designed for pooled analysis. At 12 weeks, in the 3-trial pooled analysis, rosuvastatin 10 mg (n = 389) showed significantly greater reductions in all 4 lipid ratios compared with atorvastatin 10 mg (n = 393) (p <0.001). The mean percent reduction from baseline in the LDL cholesterol/HDL cholesterol ratio was 51% in patients treated with rosuvastatin 10 mg versus 39% in patients treated with atorvastatin 10 mg. In the 2-trial pooled analysis, treatment with rosuvastatin 10 mg (n = 226) also resulted in significantly greater reductions in all 4 lipid ratios compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (p <0.001). Mean percent reductions from baseline in the LDL cholesterol/HDL cholesterol ratio were 52%, 39%, and 30% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in these 2 trials.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>12646340</pmid><doi>10.1016/S0002-9149(03)00005-5</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2003-03, Vol.91 (5), p.20-23 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73117882 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Anticholesteremic Agents - therapeutic use Apolipoproteins - blood Atorvastatin Cholesterol, HDL - blood Cholesterol, LDL - blood Coronary Disease - blood Coronary Disease - etiology Coronary Disease - prevention & control Double-Blind Method Europe Female Fluorobenzenes - therapeutic use Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - blood Hypercholesterolemia - complications Hypercholesterolemia - drug therapy Least-Squares Analysis Lipids - blood Male Middle Aged Pravastatin - therapeutic use Prospective Studies Pyrimidines Pyrroles - therapeutic use Randomized Controlled Trials as Topic Rosuvastatin Calcium Simvastatin - therapeutic use Sulfonamides Treatment Outcome |
| title | Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T14%3A24%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20and%20apolipoprotein%20ratios:%20association%20with%20coronary%20artery%20disease%20and%20effects%20of%20rosuvastatin%20compared%20with%20atorvastatin,%20pravastatin,%20and%20simvastatin&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Rader,%20Daniel%20J&rft.date=2003-03-06&rft.volume=91&rft.issue=5&rft.spage=20&rft.epage=23&rft.pages=20-23&rft.issn=0002-9149&rft.eissn=1879-1913&rft_id=info:doi/10.1016/S0002-9149(03)00005-5&rft_dat=%3Cproquest_cross%3E73117882%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73117882&rft_id=info:pmid/12646340&rft_els_id=S0002914903000055&rfr_iscdi=true |